跳至主要内容
临床试验/JPRN-UMIN000022491
JPRN-UMIN000022491已完成未知

Prediction of efficacy to simeprevir-based triple therapy in patients with genotype 1b and high viral load - Prediction of efficacy to simeprevir-based triple therapy in patients with genotype 1b and high viral load

Wakayama Medical University0 个研究点目标入组 100 人开始时间: 2016年5月27日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 100years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) pregnant women, women who may have been pregnant, lactating women, men whose partners were pregnant, or men whose partners hoped to become pregnant; 2) patients who used shosaikoto (a Kampo medicine); 3) intractable heart disease; 4) renal failure or renal dysfunction with creatinine clearance <50 mL/min; 5) patients with uncontrollable psychoneurotic disorders; 6) hemoglobin (Hb) level <11 g/dL; 7) platelet count <70,000/mm3; 8) white blood cell count <1500/mm3 (or granulocyte count <1000/mm3); and 9) hepatic failure or all types of cancer.

研究者

相似试验